Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Cancer Metabolism Based Therapeutics: Novel Strategies to Kill Cancer

Roots Analysis
Posted on: 28 Mar 18

Roots Analysis has announced the addition of “Cancer Metabolism Based Therapeutics Market, 2017-2030” report to its portfolio. The report provides an extensive study on the current landscape of the pipeline of novel drugs that target the metabolic pathways in cancer cells and features a detailed discussion on the likely future potential. The primary focus of the report is on drugs that bring about metabolic reprogramming in cancer cells by altering / inhibiting the activity of key enzymes / transporters that are a part of glucose metabolism, amino acid metabolism, TCA cycle, lipid metabolism, nucleotide metabolism and pentose phosphate pathway. 

 

Neha Agarwal, the principle analyst, said, “Currently, there are several molecules that are under preclinical and clinical evaluation and extensive research is underway to explore the potential of certain enzymes of metabolic pathways as therapeutic targets. Glycolysis, a primitive pathway utilized by cancer cells to harness energy from glucose, has been extensively researched. It is followed by the TCA cycle and various amino acid metabolism pathways.”

 

Despite the fact that this field is still in the early stages, there are many active players engaged in this area. A large proportion of players (on the basis of the number of molecules under development) are small-sized companies and start-ups. In fact, well-known, big pharma companies have also partnered with the smaller players to support discovery and development of such therapies. Our research indicates that there are several players with mid / late-stage clinical candidates that are likely to enter the market in the coming decade; examples include Agios Pharmaceuticals, Celgene, Polaris Group, Bio-Cancer Treatment International, BERG Health, Cornerstone Pharmaceuticals, Taiho Pharmaceutical, Novartis and 3-V Biosciences. Several academic / research institutes are also conducting extensive R&D in this field. Examples include (in alphabetical order) Cancer Research Technology (a part of Cancer Research UK), European Molecular Biology Laboratory, Ludwig Institute for Cancer Research, MD Anderson Cancer Center, National Cancer Institute (NCI), University of Florida, University of Louisville’s James Graham Brown Cancer Center, Wake Forest University and Weill Cornell Medical College.

Agarwal further stated, “Angel investors, venture capitalists and funding programs of various other organizations have provided monetary assistance to start-ups / small companies to pace up their R&D programs. A sum of close to USD 1.3 billion has been invested in this domain over the past few years alone.”

Amongst other things, the report covers:

  • The current state of the market with respect to key players, phase of development of pipeline products (both clinical and preclinical / discovery), target enzymes / metabolic pathways and key disease indications.
  • Comprehensive profiles of clinical stage (phase III, phase II/III, phase II, phase II (planned)) molecules highlighting details on development of the drug, key clinical trials, clinical trial endpoints, key preclinical / clinical findings, developer details including their financial performance (if available) and future market potential.
  • Various investments and grants received by companies focused in this area in order to accelerate and support ongoing R&D activities.
  • An analysis of the partnerships that have taken place in the recent past covering product development / commercialization agreements, research collaborations, clinical trial collaborations, license agreements, mergers / acquisitions and other deals signed between various stakeholders in the industry.
  • A detailed distribution of the pipeline in the form of a schematic funnel analysis, an overview of the landscape of industry developers (small, mid-sized and large players) and the geographical distribution of the companies involved in the development of cancer metabolism-based therapeutics.
  • Identification of the key targets, shortlisted based on dot-plot analysis, three-dimensional bubble analysis and five-dimensional spider-web analysis. Relevant parameters such as number of publications, grant programs, number of clinical trials, phase of development, and number of companies developing drugs for specific targets were considered for these analyses.

 

The 263 page report includes informed estimates of the potential future sales of different cancer metabolism based therapeutics. The opinions and insights discussed in this report were influenced by valuable inputs from senior stakeholders in the industry. The report features detailed transcripts of interviews held with Raul Mostoslavsky (Associate Professor, Medicine, Harvard Medical School) and Magdalena Marciniak (Business Alliance Manager, Selvita S.A.).

 

For additional details, please visit 

https://www.rootsanalysis.com/reports/view_document/cancer-metabolism-based-therapeutics-2017-2030/162.html

 

or email sales@rootsanalysis.com

 

Contact:

Gaurav Chaudhary

+1-604-595-4954
gaurav.chaudhary@rootsanalysis.com

Editor's Details

Gaurav Chaudhary
Roots Analysis
www.rootsanalysis.com
+1-604-595-4954
gaurav.chaudhary@rootsanalysis.com

Last updated on: 28/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.